Skip to content
OpenCapital
Get started

Bio-Rad Laboratories BIO Q1 2026 earnings

Reported April 30, 2026 · After market close

Revenue$592.1MBeat by $2.2M
EPS$1.89Miss by $0.10
Revenue estimate$589.9M
EPS estimate$1.99

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$624.0M
EPS estimate$1.75

Financials

Q1 2026

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$8.47B+22.9%
Enterprise value$8.95B+12.7%
P/E50.2×+28.6×
P/S3.3×+0.6×

Profitability

See full
Gross margin51.9%-1.6pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Segments

By geography

See full
Europe$206.8M+3.5%
Asia Pacific$110.4M+6.1%
Americas$45.1M+13.3%

By segment

See full
Clinical Diagnostics$363.6M+1.9%
Life Science$228.5M0.0%

Versus estimates

Revenue

Q1 2026$592.1MBeat by $2.2M
Q4 2025$693.2MBeat by $4.4MQ3 2025$653.0MMiss by $41.6MQ2 2025$651.6MBeat by $17.8MQ1 2025$585.4MBeat by $12.2MQ4 2024$667.5MMiss by $12.3M

Diluted EPS

Q1 2026$1.89Miss by $0.10
Q4 2025$2.51Miss by $0.06Q3 2025$2.26Miss by $0.04Q2 2025$2.61Beat by $0.68Q1 2025$2.54Beat by $0.81Q4 2024$2.90Beat by $0.04

Ask the moment Bio-Rad Laboratories reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Bio-Rad Laboratories report Q1 2026 earnings?
Bio-Rad Laboratories (BIO) reported Q1 2026 earnings on April 30, 2026 after market close.
What were Bio-Rad Laboratories's Q1 2026 revenue and EPS?
Bio-Rad Laboratories reported revenue of $592.1M and eps of $1.89 for Q1 2026.
Did Bio-Rad Laboratories beat estimates in Q1 2026?
Revenue beat the consensus estimate of $589.9M by $2.2M. EPS missed the consensus estimate of $1.99 by $0.10.
How did Bio-Rad Laboratories's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1.1% from $585.4M a year earlier and eps declined 25.6% from $2.54.
Where can I find Bio-Rad Laboratories's Q1 2026 SEC filings?
You can read the 8-K earnings release (0000012208-26-000034) and the 10-Q periodic report (0000012208-26-000035) directly on SEC EDGAR. The filing index links above go to sec.gov.